RESULTS: Consecutive patients with ischemic stroke treated with intravenous thrombolysis or endovascular thrombectomy were analyzed. DAOH-90 was calculated from a national minimum data set, a mandatory nationwide administrative database. mRS score at day 90 (mRS-90) was assessed with in-person or telephone interviews. The study included 1278 patients with ischemic stroke (714 male, median age 70 [59-79], median National Institutes of Health Stroke Scale score 14 [9-20]). Median DAOH-90 was 71 [29-84] and median mRS-90 score was 3 [2-5]. DAOH-90 was correlated with admission National Institutes of Health Stroke Scale score (Spearman rho -0.44, P<0.001) and Alberta Stroke Program Early CT [Computed Tomography] Score (Spearman rho 0.24, P<0.001). There was a strong association between mRS-90 and DAOH-90 (Spearman rho correlation -0.79, P<0.001). Area under receiver operating curve for predicting mRS score >0 was 0.86 (95% CI, 0.84-0.88), mRS score >1 was 0.88 (95% CI, 0.86-0.90) and mRS score >2 was 0.90 (95% CI, 0.89-0.92).
CONCLUSIONS: In patients with stroke treated with reperfusion therapies, DAOH-90 shows reasonable comparability to the more established outcome measure of mRS-90. DAOH-90 can be readily obtained from administrative databases and therefore has the potential to be used in large-scale clinical trials and comparative effectiveness studies.
结果:分析连续接受静脉溶栓或血管内血栓切除术治疗的缺血性卒中患者。DAOH-90是根据国家最低数据集计算的,强制性的全国性行政数据库。第90天的mRS评分(mRS-90)通过面对面或电话访谈进行评估。该研究包括1278例缺血性卒中患者(714例男性,中位年龄70[59-79],美国国立卫生研究院卒中量表中位数评分14[9-20])。DAOH-90中位数为71[29-84],mRS-90中位数为3[2-5]。DAOH-90与美国国立卫生研究院卒中量表评分(Spearmanrho-0.44,P<0.001)和Alberta卒中项目早期CT[计算机断层扫描]评分(Spearmanrho0.24,P<0.001)相关。mRS-90和DAOH-90之间有很强的相关性(Spearmanrho相关性-0.79,P<0.001)。预测mRS评分>0的受试者工作曲线下面积为0.86(95%CI,0.84-0.88),mRS评分>1为0.88(95%CI,0.86-0.90),mRS评分>2为0.90(95%CI,0.89-0.92)。
结论:在接受再灌注治疗的中风患者中,DAOH-90与mRS-90的更确定的结果测量显示出合理的可比性。DAOH-90可以很容易地从管理数据库中获得,因此具有用于大规模临床试验和比较有效性研究的潜力。